RxDoctor Payments Data

Heather Dennis

Nurse Practitioner · Newark, DENPI 1881112787

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,273 of the $3,740 with a category attached, or 60.8%. Abbott accounts for 90.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $2,648 and has fallen 82.0% since, to $477 in 2025. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,740in general payments, 2019–2025

Across 100 payments — averaging $37.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Daxor Corporation$91
  • Kestra Medical Technology Services, Inc.$46
  • Pfizer$40
  • Alnylam Pharmaceuticals Inc.$39
  • Bridgebio Pharma, Inc.$33
  • plus $103 from 4 others

What the payments were for

  • Travel & lodging$1,39837%
  • Food & beverage$2,27361%
  • Education$692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,740 in reported general payments places this provider in the 90th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$16,577
Medicare patients
86
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sildenafil Citrate18$10,675
EntrestoSacubitril/Valsartan11$8,542
Bumetanide55$2,664
Metoprolol Succinate40$816
Hydralazine Hcl29$683
Warfarin Sodium43$657
Potassium Chloride30$460
Amiodarone Hcl21$372
Atorvastatin Calcium13$207
Spironolactone23$189
Furosemide30$182
Carvedilol14$103
Mirtazapine11$96

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →